This is a preview of subscription content, log in via an institution to check access.
References
Kapoor R, et al. Cost effectiveness analysis of HLA-B*5701 genotyping in newly diagnosed persons living with HIV/AIDS in Singapore, by ethnicity. 20th International AIDS Conference : abstr. THPE419, 22 Jul 2014.
Wilkins E, et al. An analysis of cost and health outcomes associated with tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV?1 infection in the United Kingdom. 20th International AIDS Conference : abstr. THPE420, 22 Jul 2014.
Finnell SME, et al. Cost-effectiveness of first line LPV/r-based regimen for HIV infected infants in Western Kenya. 20th International AIDS Conference : abstr. THPE423, 22 Jul 2014.
Tagar E, et al. Multi-country analysis of the cost implications of HIV treatment scale-up. 20th International AIDS Conference : abstr. WEAE0105LB, 22 Jul 2014.
Ishikawa N, et al. Expanded health impact and its cost-effectiveness of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia. 20th International AIDS Conference : abstr. THPE410, 22 Jul 2014.
Rights and permissions
About this article
Cite this article
News from IAC. PharmacoEcon Outcomes News 710, 19–20 (2014). https://doi.org/10.1007/s40274-014-1492-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1492-9